Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
20 Fevereiro 2024 - 10:30AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced that it plans to release fourth
quarter 2023 financial and operating results prior to market open
on Tuesday, March 5th, 2024. The Company will host a conference
call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode
via webcast at
https://edge.media-server.com/mmc/p/7cha7jae. To
listen to the conference call on your telephone, participants may
register for the call here. While it is not
required, it is recommended you join 10 minutes prior to the event
start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as
physical health. As a global leader in neuroscience, Neuronetics is
redefining patient and physician expectations with its NeuroStar
Advanced Therapy for Mental Health. NeuroStar is a non-drug,
noninvasive treatment that can improve the quality of life for
people suffering from neurohealth conditions when traditional
medication hasn’t helped. In the United States, NeuroStar is
FDA-cleared for adults with major depressive disorder (MDD), as an
adjunct for adults with obsessive-compulsive disorder (OCD), and to
decrease anxiety symptoms in adult patients with MDD that may
exhibit comorbid anxiety symptoms (anxious depression). NeuroStar
Advanced Therapy is the leading transcranial magnetic stimulation
(TMS) treatment for MDD in adults with over 5.9 million treatments
delivered. NeuroStar is backed by the largest clinical data set of
any TMS system for depression, including the world’s largest
depression Outcomes Registry. Neuronetics is committed to
transforming lives by offering an exceptional treatment that
produces extraordinary results. For safety and prescribing
information, www.neurostar.com.
Investor Contact:Mike Vallie or Mark
KlausnerICR Westwicke443-213-0499ir@neuronetics.com
Media
Contact:EvolveMKD646-517-4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024